Renaissance Technologies LLC lifted its position in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 0.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,992,601 shares of the company's stock after acquiring an additional 13,604 shares during the period. Renaissance Technologies LLC owned 4.32% of Pacira BioSciences worth $37,541,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other large investors have also recently made changes to their positions in the company. Caitlin John LLC boosted its stake in Pacira BioSciences by 1,850.0% during the fourth quarter. Caitlin John LLC now owns 1,872 shares of the company's stock worth $35,000 after buying an additional 1,776 shares during the last quarter. Nisa Investment Advisors LLC increased its position in Pacira BioSciences by 495.3% during the fourth quarter. Nisa Investment Advisors LLC now owns 3,304 shares of the company's stock worth $62,000 after purchasing an additional 2,749 shares during the last quarter. PNC Financial Services Group Inc. boosted its holdings in Pacira BioSciences by 16.6% in the 4th quarter. PNC Financial Services Group Inc. now owns 3,597 shares of the company's stock valued at $68,000 after purchasing an additional 513 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in shares of Pacira BioSciences by 10.3% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 9,790 shares of the company's stock worth $184,000 after buying an additional 918 shares during the last quarter. Finally, Raymond James Financial Inc. acquired a new position in Pacira BioSciences in the fourth quarter valued at approximately $190,000. 99.73% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Ratings Changes
Several equities analysts have recently commented on the company. Royal Bank of Canada reaffirmed a "sector perform" rating and issued a $18.00 price target on shares of Pacira BioSciences in a research note on Tuesday, January 14th. HC Wainwright boosted their price target on shares of Pacira BioSciences from $48.00 to $65.00 and gave the company a "buy" rating in a research note on Tuesday, April 8th. Needham & Company LLC reiterated a "buy" rating and issued a $32.00 target price on shares of Pacira BioSciences in a report on Tuesday, April 8th. Truist Financial raised Pacira BioSciences from a "sell" rating to a "hold" rating and lifted their price objective for the company from $8.00 to $25.00 in a research note on Thursday, January 30th. Finally, Barclays increased their price target on shares of Pacira BioSciences from $17.00 to $24.00 and gave the stock an "overweight" rating in a research report on Friday, February 28th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat.com, Pacira BioSciences has a consensus rating of "Hold" and a consensus price target of $26.67.
Get Our Latest Stock Analysis on PCRX
Pacira BioSciences Stock Up 1.2 %
Shares of NASDAQ PCRX traded up $0.30 during mid-day trading on Thursday, reaching $24.77. The company had a trading volume of 106,842 shares, compared to its average volume of 967,227. The firm has a 50 day simple moving average of $24.64 and a two-hundred day simple moving average of $20.98. Pacira BioSciences, Inc. has a 52-week low of $11.16 and a 52-week high of $31.67. The company has a current ratio of 2.25, a quick ratio of 1.89 and a debt-to-equity ratio of 0.51. The stock has a market cap of $1.15 billion, a P/E ratio of -12.19 and a beta of 0.71.
About Pacira BioSciences
(
Free Report)
Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.
Further Reading
Before you consider Pacira BioSciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pacira BioSciences wasn't on the list.
While Pacira BioSciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
